Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01522612
Other study ID # EORTC-40085-75083
Secondary ID 2011-002947-83
Status Terminated
Phase Phase 2
First received January 27, 2012
Last updated June 9, 2016
Start date April 2013
Est. completion date January 2015

Study information

Verified date June 2016
Source European Organisation for Research and Treatment of Cancer - EORTC
Contact n/a
Is FDA regulated No
Health authority Belgium: Federal Agency for Medicinal Products and Health ProductsGermany: Federal Institute for Drugs and Medical DevicesItaly: The Italian Medicines AgencySpain: Agencia Española de Medicamentos y Productos SanitariosUnited Kingdom: Medicines and Healthcare Products Regulatory AgencyFrance: Agence Nationale de Sécurité du Médicament et des produits de santé
Study type Interventional

Clinical Trial Summary

OBJECTIVE: The principal objective of the trial is to evaluate whether the addition of cetuximab associated with 5-fluorouracil in elderly patients with KRAS wild type advanced colorectal cancer (CRC) prolongs Progression Free Survival, compared with 5-fluorouracil alone.


Description:

The primary efficacy analyses will be performed on the Intention-to-treat population.

The safety analyses will be performed on the Safety population.

- Median PFS and OS in each treatment arm with its 95% CI, estimated by the Kaplan-Meier technique

- Response rates by treatment arm with their exact 95% CI

- IADL sum score, G8 sum score and social situation by treatment arm at baseline and at each timepoint of assessment

- QoL scores from the EORTC QLQ-C30 and QLQ-ELD14 modules by treatment arm at baseline and at each timepoint of assessment

- Safety data by treatment arm in the Safety population. Worst toxicity grade over all cycles according to the CTCAE criteria version 4.0 by treatment arm.

- Pharmaco-economics evaluation

Summary of proposed Phase II trial characteristics:

1. Total number of randomized patients: 150.

2. Total number of events at phase II analysis for primary endpoint: 110.

3. Total number of patients screened over the phase II: 250.

4. Total number of patients treated with cetuximab for the Phase II study: 75.

5. Maximum study duration: 19 months.

In the present study, HRQoL is an important secondary endpoint. The objective of the HRQoL data collection in this Phase II trial is to assess the impact of the addition of cetuximab on patients' HRQoL during treatment.

The hypothesis is that there will be no difference in patients' HRQoL between both treatment arms during treatment. The HRQoL domains (from the EORTC QLQ-C30 module) which are expected to be affected by treatment (to the same extent in both arms) are Global health status, Fatigue, Pain and Stool habits.


Recruitment information / eligibility

Status Terminated
Enrollment 5
Est. completion date January 2015
Est. primary completion date January 2015
Accepts healthy volunteers No
Gender Both
Age group 70 Years and older
Eligibility Inclusion Criteria:

- Pathologically confirmed metastatic colorectal cancer

- Measurable disease according to RECIST V1.1

- Histological local review and analysis of KRAS

- Age = 80 or = 70 in combination with functional restrictions defined as limitation in at least 2 of 8 IADL

- WHO performance status 0, 1 or 2

- Adequate bone marrow reserves, hepatic function & renal function

- Normal 12 lead ECG without clinically significant abnormalities

- Written informed consent before randomization according to ICH/EU GCP, and local, national and international regulations

Exclusion Criteria:

- Prior systemic chemotherapy for metastatic disease

- Previous exposure to EGFR or VEGF/VEGFR targeted therapy

- Patients may have received chemotherapy in the adjuvant or neoadjuvant setting (CRC). The treatment-free interval should be 6 months or more from the end of (neo-)adjuvant therapy

- Previous radiotherapy, either in the adjuvant setting or for the treatment of bone metastases, is allowed provided that the measurable lesions are outside the radiation fields

- Persistence of clinically relevant treatment-related toxicities from previous chemotherapy and/or radiotherapy (adjuvant or neo-adjuvant setting)

- Treatment with other investigational drugs or treatment in another clinical trial within the past four weeks before start of treatment or concomitantly with this trial

- Known alcohol or drug abuse

- Clinically significant cardiovascular disease

- Evidence of uncontrolled medical comorbidities despite adequate treatment

- Patients who have suffered a cerebrovascular accident or transient ischemic attack within the past 12 months

- History, within the past 5 years, of malignancies other than CRC

- Psychological, familial, sociological, or geographical condition potentially hampering compliance with the study protocol and followup schedule

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Cetuximab
500 mg/m2 on day 1, Every 14 days Intravenously
5-fluorouracil
Every 2 weeks, 400 mg/m2 on day 1; 2400 mg/m2 from day 1 to day 3, intravenously
leucovorin
Every 2 weeks, Racemic leucovorin 200 mg/m2 or l-leucovorin 100 mg/m2 on day 1, intravenously

Locations

Country Name City State
Belgium AZ Turnhout - Campus Sint Elisabeth Turnhout
Cyprus Bank Of Cyprus Oncology Centre Nicosia
Spain Hospital General Vall D'Hebron Barcelona

Sponsors (2)

Lead Sponsor Collaborator
European Organisation for Research and Treatment of Cancer - EORTC Merck KGaA

Countries where clinical trial is conducted

Belgium,  Cyprus,  Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression free survival Progression will be defined according to the "RECIST V1.1" 19 months from first patient in No
Secondary Overall Survival 19 months from first patient in No
Secondary Response Rate according to the RECIST V1.1 19 months from first patient in No
Secondary Change in Instrumental Activities of Daily Living (IADL) score 19 months from first patient in No
Secondary Change in G8 geriatric assessment screening tool 19 months from first patient in No
Secondary Change in social situation 19 months from first patient in No
Secondary Score of Quality of Life (EORTC-QLQ C30 and QLQ-ELD14) 14 days before randomization; 6 weeks, 14 weeks, 22 weeks and 38 weeks after randomization; 30 days after last treatment administration No
Secondary Occurrence of adverse events Adverse events will be graded according to the "Common Terminology Criteria for Adverse events" CTCAE,version 4.0. 19 months from first patient in Yes
Secondary Health Economy assessments 19 months from first patient in No
Secondary Score of elderly minimal dataset comprehensive geriatric assessment (EMDCGA), as evaluated by G8 instrument 14 days before randomization; 6 weeks, 14 weeks, 22 weeks and 38 weeks after randomization; 30 days after last treatment administration No
Secondary Score of elderly minimal dataset comprehensive geriatric assessment (EMDCGA), as evaluated by Instrumental Activities of Daily Life (IADL) questionnaire 14 days before randomization; 6 weeks, 14 weeks, 22 weeks and 38 weeks after randomization; 30 days after last treatment administration No
Secondary Score of elderly minimal dataset comprehensive geriatric assessment (EMDCGA), as evaluated by social situation questionnaire 14 days before randomization; 6 weeks, 14 weeks, 22 weeks and 38 weeks after randomization; 30 days after last treatment administration No
See also
  Status Clinical Trial Phase
Recruiting NCT03941080 - Gut Microbiome Dynamics in Metastasized or Irresectable Colorectal Cancer
Completed NCT03213314 - HepaT1ca: Quantifying Liver Health in Surgical Candidates for Liver Malignancies N/A
Completed NCT03647839 - Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer Phase 2
Recruiting NCT05057052 - Cryoablation Combined With Sintilimab Plus Regorafenib In Previously Treated Colorectal Cancer Liver Metastasis Phase 2
Terminated NCT02316496 - Rechallenge of Cetuximab Combined With Irinotecan as Third-line Chemotherapy in Patients With Metastatic Colorectal Cancer - Phase II Study Phase 2
Completed NCT03251612 - Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer Phase 2
Completed NCT02380443 - AlloStim® Immunotherapy Dosing Alone or in Combination With Cryoablation in Metastatic Colorectal Cancer Phase 2
Recruiting NCT02149784 - Effectiveness Study of Resection of Primary Tumor in Stage IV Colorectal Cancer Patients Phase 3
Recruiting NCT01959061 - Efficacy and Safety of Raltitrexed-based Transarterial Chemoembolisation(TACE)for Colorectal Cancer Liver Metastases Phase 4
Terminated NCT01668680 - Maintenance Metronomic Chemotherapy for Metastatic Colorectal Carcinoma Phase 2
Recruiting NCT05068531 - Early Detection of Treatment Failure in Metastatic Colorectal Cancer Patients
Not yet recruiting NCT04525807 - Precision Medicine for Colorectal Cancer Liver Metastasis Guided by Multi-omics Data Under the Umbrella Theory
Completed NCT04482608 - The mCRC Patients With pMMR/MSS or dMMR/MSI-H Status Received Palliative Chemotherapy Efficacy and Survival
Recruiting NCT03193710 - The Effects of General Anesthetics on Lymphocytes in Patients Undergoing Colorectal Cancer Resection and Mechanism Involved N/A
Recruiting NCT04854213 - PRELUDE-1 (Prospective Evaluation of Radiotherapy-induced Biologic Effects in Colorectal Cancer Oligometastatic Patients With LUng-limited Disease: Evolution of Cancer Genetics and Regulatory Immune Cells) N/A
Suspended NCT04108481 - Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer Phase 1/Phase 2
Completed NCT03144804 - A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer Phase 2
Completed NCT03142516 - FOLFIRI + Panitumumab First-line Treatment in Elderly Patients With Unresectable Metastatic Colorectal Cancer, RAS/BRAF Wild-type and Good Performance Status Phase 2
Active, not recruiting NCT01910610 - Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer Phase 3
Recruiting NCT05759728 - A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer Phase 1/Phase 2

External Links